EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The tumor stroma ratio in stage II and III colon cancer: Prognostic impact and evaluation of predictive value

Floor Heilijgers, Marie-Christine E. Bakker, Ingrid A. Franken, Miriam Cuatrecasas, Koen C. M. J. Peeters, Hein Putter, Frank M. Speetjens, Jeanine M. L. Roodhart, Wilma E. Mesker

Therapeutic Advances in Medical Oncology · 2026-11 · 18

DOI: 10.1177/17588359261504800 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 07.11.2026. Verfasst von Floor Heilijgers und 8 weiteren Autor:innen. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bollenstreekfonds, Hillegom, Dutch Cancer Society, Stichting Fonds Oncologie Holland.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Current pathological biomarkers and tumor-node-metastasis (TNM) staging provide limited precision for guiding adjuvant chemotherapy (ACT) in colon cancer. The Tumor Stroma Ratio (TSR) is a histopathological prognostic biomarker and may predict ACT benefit.

Objectives

This study evaluated the predictive value of TSR for ACT benefit in patients with stage II and III colon cancer from the UNITED trial and the Netherlands Cancer Registry.

Design

A retrospective cohort study using trial and real-world data.

Methods

TSR was assessed on H&E-stained slides from surgical resection specimens of stage II and III colon cancer patients and categorized as stroma-low (≤50%) or stroma-high (>50%). The primary endpoint was recurrence-free rate (RR). Disease-free survival (DFS) and overall survival (OS) were secondary outcomes. Missing data was handled using multiple imputation by chained equations. To adjust for baseline differences in the probability of receiving ACT, inverse probability of treatment weighting with stabilized weights was applied. Cox proportional hazards models were used to assess prognostic and predictive effects, including an interaction term between ACT and TSR.

Results

This study included 2980 patients; 57.1% received ACT and 38.9% were classified as stroma-high. Stroma-high patients demonstrated significant worse survival outcomes (RR: HR 1.85 with 95%CI 1.54 – 2.23, p

Förderung

  • Bollenstreekfonds, Hillegom
  • Dutch Cancer Society
  • Stichting Fonds Oncologie Holland
  • Health Holland

Zitieren

APA

Heilijgers, F., Bakker, M. E., Franken, I. A., Cuatrecasas, M., Peeters, K. C. M. J., Putter, H., Speetjens, F. M., Roodhart, J. M. L., & Mesker, W. E. (2026). The tumor stroma ratio in stage II and III colon cancer: Prognostic impact and evaluation of predictive value. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261504800

Vancouver

Heilijgers F, Bakker ME, Franken IA, Cuatrecasas M, Peeters KCMJ, Putter H, et al. The tumor stroma ratio in stage II and III colon cancer: Prognostic impact and evaluation of predictive value. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261504800

BibTeX
@article{Heilijgers2026,
  author = {Heilijgers, Floor and Bakker, Marie-Christine E. and Franken, Ingrid A. and Cuatrecasas, Miriam and Peeters, Koen C. M. J. and Putter, Hein and Speetjens, Frank M. and Roodhart, Jeanine M. L. and Mesker, Wilma E.},
  title = {The tumor stroma ratio in stage II and III colon cancer: Prognostic impact and evaluation of predictive value},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359261504800}
}
Kostenlos starten →